Scalper1 News
Shares of genetic-testing company Myriad Genetics (MYGN) tumbled Wednesday after the company’s guidance missed estimates late Tuesday, though analyst reaction was more sanguine. Myriad Genetics stock was down 10% in afternoon trading in the stock market today, near 35. Leerink analyst Dan Leonard raised his price target to 38 from 35, writing in his note Wednesday that though the near-term outlook was soft, the uptake of the new MyRisk hereditary Scalper1 News
Scalper1 News